Skip to Main Content

Author Details

John C Bell
Ottawa Hospital Research Institute
1979
267
71
PMIDPaper TitleJournal TitlePublished Year
36674550Extracellular Vesicles and Viruses: Two Intertwined Entities.Int J Mol Sci2023
37153626Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.Front Immunol2023
37242495Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.Pharmaceuticals (Basel)2023
37236967Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.Nat Commun2023
37100284Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.J Biol Chem2023
36969187Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy <i>via</i> lipid modulation of the tumor microenvironment.Front Immunol2023
36713447CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.Front Immunol2023
34328726Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.J Med Chem2022
35439304Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.Cancer Immunol Res2022
35603308Advances in oncolytic virotherapy.Commun Med (Lond)2022
35393414Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.Nat Commun2022
35526097Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.Mol Ther2022
35619558Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery.Mol Ther2022
36405739Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.Front Immunol2022
36601119CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.Front Immunol2022
36004308A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S.NAR Genom Bioinform2022
35104497Robust envelope exchange platform for oncolytic measles virus.J Virol Methods2022
34687845Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.Mol Ther2022
33976179Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.Nat Commun2021
37579261Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic.ACS Nanosci Au2021
33706157SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.Biosens Bioelectron2021
33668756Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.Int J Mol Sci2021
33555379Personalized oncology and BRAF<sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlation.J Cancer Res Clin Oncol2021
33578036Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.Mol Ther2021
34658235Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.ACS Infect Dis2021
34141871MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.Mol Ther Oncolytics2021
31486028Introduction to Oncolytic Virotherapy.Methods Mol Biol2020
32053093Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations.J Gen Virol2020
32718830Engineering and combining oncolytic measles virus for cancer therapy.Cytokine Growth Factor Rev2020
32872641Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.Membranes (Basel)2020
32722184Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis.Cancers (Basel)2020
32248971Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro.Biochem Biophys Res Commun2020
32304670Check and Checkmate: Battling Cancer with Multiplex Immunotherapy.Mol Ther2020
32297534Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity.Expert Opin Biol Ther2020
32489273The Canadian Cancer Research Conference 2019.Curr Oncol2020
32346612Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy.Mol Ther Oncolytics2020
32393835Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers.Oncogene2020
30422820Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.J Clin Invest2019
31428674Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy.Mol Ther Oncolytics2019
31193718An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate <i>In Vivo</i>.Mol Ther Oncolytics2019
30794777SnapShot: Cancer Immunotherapy with Oncolytic Viruses.Cell2019
30755678Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.Sci Rep2019
30875126Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.Stem Cells2019
28830732cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.Trends Immunol2018
29900060Transforming the prostatic tumor microenvironment with oncolytic virotherapy.Oncoimmunology2018
30198904Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.J Clin Invest2018
30112421Use of Precision-Cut Lung Slices as an <i>Ex Vivo</i> Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy.Mol Ther Methods Clin Dev2018
30138450Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.PLoS Pathog2018
29921327Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.J Immunother Cancer2018
30546947Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.Oncoimmunology2018
  • 1 - 50 of 267

Recommended Authors

Jennifer R Hamilton
University of California berkeley
Career Start Year 2011
Number of shared co-authors 0
Jianying Zhang
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 1
Thomas J Gardner
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 0
Min Luo
Institute of Biomedical Science and Children's Hospital, Fudan University
Career Start Year 2006
Number of shared co-authors 0
James R Whittle
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2006
Number of shared co-authors 0
Aleksandra A Pandyra
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2003
Number of shared co-authors 1
Hongmei Ruan
University of California san francisco
Career Start Year 2003
Number of shared co-authors 0
Travis R Taylor
University of Toledo
Career Start Year 2002
Number of shared co-authors 0
Marta M Alonso
CIMA-Universidad de Navarra
Career Start Year 2001
Number of shared co-authors 3
Michael Denton
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2001
Number of shared co-authors 0
Sunil J Advani
Moores Cancer Center, University of California San Diego
Career Start Year 1997
Number of shared co-authors 0
Renee C Ireton
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 1997
Number of shared co-authors 0
Jan E Carette
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 0
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 3
J??rgen Haas
University of Edinburgh
Career Start Year 1996
Number of shared co-authors 0
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Career Start Year 1996
Number of shared co-authors 2
Zhiya Yu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 0
Yu-Tsueng Liu
University of California San Diego
Career Start Year 1994
Number of shared co-authors 0
Ren Sun
University of California los angeles
Career Start Year 1992
Number of shared co-authors 0
Veena Kapoor
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
Candelaria Gomez-Manzano
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 6
Juan Fueyo
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 6
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Career Start Year 1985
Number of shared co-authors 3
Nicholas P Restifo
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 1985
Number of shared co-authors 1
Elizabeth M Jaffee
Convergence Institute, Johns Hopkins University
Career Start Year 1985
Number of shared co-authors 2
John T Schiller
David Geffen School of Medicine at university of california los angeles
Career Start Year 1984
Number of shared co-authors 2
Steven F Dowdy
University of California
Career Start Year 1982
Number of shared co-authors 0
Luigi Naldini
Vita-Salute San Raffaele University
Career Start Year 1980
Number of shared co-authors 2
Judy Lieberman
Boston Children's Hospital
Career Start Year 1978
Number of shared co-authors 0
George Yancey Gillespie
Heersink School of Medicine, The University of Alabama at Birmingham
Career Start Year 1970
Number of shared co-authors 3

Collaborators

Jean-Simon Diallo
Ottawa Hospital Research Institute, University of Ottawa
Co-authored papers 48
Carolina S Ilkow
Ottawa Hospital Research Institute
Co-authored papers 32
Rebecca C Auer
The Ottawa Hospital Research Institute
Co-authored papers 25
Christiano Tanese de Souza
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 18
Taha Azad
Ottawa Hospital Research Institute
Co-authored papers 18
Dominic G Roy
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
Co-authored papers 17
Mathieu J F Crupi
Cancer Research Institute, Queen's University
Co-authored papers 17
Ragunath Singaravelu
Ottawa Hospital Research Institute
Co-authored papers 15
Adrian Pelin
University of Ottawa
Co-authored papers 15
Julia Petryk
Ottawa Hospital Research Institute
Co-authored papers 13
Zaid Taha
Ottawa Hospital Research Institute, University of Ottawa
Co-authored papers 12
Almohanad A Alkayyal
College of Applied Medical Sciences, University of Tabuk
Co-authored papers 8
Abera Surendran
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 7
Joanna Poutou
Ottawa Hospital Research Institute
Co-authored papers 7
Brian A Keller
The Ottawa Hospital/University of Ottawa
Co-authored papers 6
Xiao-Peng He
Ottawa Hospital Research Institute
Co-authored papers 6
John W Barrett
University of Western Ontario
Co-authored papers 6
Victoria A Jennings
Leeds Institute of Medical Research at St James's, University of Leeds
Co-authored papers 6
Alan Melcher
The Institute of Cancer Research
Co-authored papers 5
Larissa A Pikor
Ottawa Hospital Research Institute
Co-authored papers 5
Sarwat T Khan
Ottawa Hospital Research Institute
Co-authored papers 4
Ladan Fazli
University of British Columbia
Co-authored papers 4
David Ron
Cambridge Institute for Medical Research, University of Cambridge
Co-authored papers 4
Tony Pawson
Co-authored papers 3
Christof von Kalle
Berlin Institute of Health at Charite-Universitatsmedizin Berlin
Co-authored papers 3
Aled M Edwards
University of Toronto
Co-authored papers 3
Marie-??ve Wedge
Ottawa Hospital Research Institute
Co-authored papers 3
Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 2
Martin E Gleave
University of British Columbia
Co-authored papers 2
Ashkan Golshani
Ottawa Institute of Systems Biology, Carleton University
Co-authored papers 2
Release 1.2